Followers | 837 |
Posts | 120337 |
Boards Moderated | 18 |
Alias Born | 09/05/2002 |
![](https://investorshub.advfn.com/uicon/14742.png?cb=1465058685)
Thursday, July 15, 2021 12:34:13 PM
https://finance.yahoo.com/news/vir-biotechnology-initiates-phase-2-123000780.html
The multi-center, open-label Phase 2 trial is designed to evaluate the safety, tolerability and efficacy of the combination of VIR-2218 and VIR-3434 in approximately 90 adult patients (ages 18 to 65) with chronic HBV infection receiving nucleot(s)ide reverse transcriptase inhibitor therapy. Both VIR-2218 and VIR-3434 will be administered via subcutaneous injection at varying dose levels over the course of the trial for a treatment period ranging from four to 20 weeks, and a follow-up period of up to 116 weeks, depending on the dosing cohort.
…VIR-2218 is an investigational small interfering ribonucleic acid (siRNA) designed to inhibit the production of all HBV proteins (X, polymerase, S and core), which may be acting as immune tolerogens. VIR-3434 is an investigational HBV-neutralizing monoclonal antibody designed to block entry of all 10 genotypes of HBV into hepatocytes, as well as reduce the level of virions and subviral particles in the blood. It has also been Fc engineered to include the XX2 “vaccinal mutation,” allowing it to potentially function as a therapeutic T cell vaccine against HBV.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent VIR News
- Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference • Business Wire • 08/22/2024 12:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:43:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:10:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:08:53 PM
- Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities • Business Wire • 08/01/2024 08:02:00 PM
- Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers • Business Wire • 08/01/2024 08:01:00 PM
- Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024 • Business Wire • 07/18/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:40:36 PM
- Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection • Business Wire • 06/26/2024 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 10:04:32 AM
- Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment • Business Wire • 06/05/2024 09:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 04:13:41 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 03:57:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 06:43:18 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 06:42:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 08:06:02 PM
- Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • Business Wire • 05/29/2024 08:05:00 PM
- Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer • Business Wire • 05/29/2024 12:05:00 PM
- Vir Biotechnology to Host 2024 Annual Meeting of Stockholders • Business Wire • 05/23/2024 08:05:00 PM
- Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 • Business Wire • 05/22/2024 12:05:00 PM
- Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024 • Business Wire • 05/21/2024 12:17:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/14/2024 08:05:39 PM
- Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results • Business Wire • 05/02/2024 08:05:00 PM
- Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024 • Business Wire • 04/30/2024 08:05:00 PM
FEATURED Element79 Gold Corp Appoints Warren Levy to Board of Directors • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM